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Abstract 
 
Pregnancy in women with severe mental illness is associated with adverse outcomes for mother and 
infant.  There are limited data on prevalence and predictors of relapse in pregnancy.  A historical 
cohort study using anonymised comprehensive electronic health records from secondary mental 
health care linked with national maternity data was carried out.  Women with a history of serious 
mental illness who were pregnant (2007-2011), and in remission at the start of pregnancy, were 
studied; severe relapse was defined as admission to acute care or self-harm.  Predictors of relapse 
were analysed using random effects logistic regression to account for repeated measures in women 
with more than one pregnancy in the study period.  In 454 pregnancies (389 women) there were 58 
(24%) relapses in women with non-affective psychoses and 25 (12%) in women with affective 
psychotic or bipolar disorders.  Independent predictors of relapse included non-affective psychosis 
(adjusted OR=2.03; 95% CI=1.16-3.54), number of recent admissions (1.37; 1.03-1.84), recent self-
harm (2.24; 1.15-4.34), substance use (2.15; 1.13-4.08), smoking (2.52; 1.26-5.02) and non-white 
ethnicity (black ethnicity: 2.37; 1.23,4.57, mixed/other ethnicity: 2.94; 1.32,6.56).  Women on no 
regular medication throughout first trimester were also at greater risk of relapse in pregnancy (1.99; 
1.05-3.75). There was no interaction between severity of illness and medication status as relapse 
predictors.  Therefore, women with non-affective psychosis and higher number of recent acute 
admissions are at significant risk of severe relapse in pregnancy.  Continuation of medication in 
women with severe mental illness who become pregnant may be protective. 
 
Keywords: psychosis; bipolar; pregnancy; relapse; medication 
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Introduction 
 
Relapse of serious mental illness (SMI; schizophrenia, related delusional disorders, affective 
psychoses and bipolar disorder) in the perinatal period is potentially devastating for a woman and 
her unborn baby.  It may impact on her ability to care for herself, and rarely but tragically result in 
custody loss of children, suicide or infanticide (Jones et al, 2014).  International confidential 
enquiries into maternal deaths highlight psychiatric illness as a leading cause (Austin et al, 2007; 
Cantwell et al, 2011; Khalifeh et al, 2016).   
 
Studies have consistently reported increased risk of relapse of psychosis in the early postpartum, 
with risk factors including history of bipolar disorder or post-partum psychosis (Jones et al, 2014; 
Munk-Olsen et al, 2009; Wesseloo et al, 2015).  There are fewer data on the course of SMI during 
pregnancy, particularly for schizophrenia.  Recently reported data indicated a 12% rate of 
hospitalisation for women with schizophrenia in pregnancy (Rochon-Terry et al, 2016).  For bipolar 
disorder some studies estimate around 8-18% relapse in pregnancy  (Di Florio et al, 2013; Grof et al, 
2000), but tertiary perinatal mental health clinics have reported substantially higher rates (71%), 
particularly in women who discontinue medication (86%) and those with more severe illness 
(Viguera et al, 2007).  Varying definitions of relapse may explain inconsistencies; some use hospital 
admission and others use clinical or research interviews to determine symptomatology, which 
identify less severe relapses.  
 
We aimed to investigate risk and predictors of severe relapse in pregnancy in a cohort of women 
with SMI. We hypothesised that: 1) diagnosis and markers of severity (non-affective SMI, recent 
admissions) and 2) first trimester medication changes (switching or discontinuation) would be 
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independently associated with relapse. We also explored interactions between diagnosis, admissions 
in two years before pregnancy and domestic violence (DV) with medication. 
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Methods 
 
Data Source 
Data came from the South London and Maudsley (SLaM) NIHR Biomedical Research Centre Clinical 
Record Interactive Search (CRIS) (Stewart et al, 2009), a large resource of comprehensive secondary 
mental health records from over 300,000 patients.  SLaM serves a catchment of around 1.2 million 
residents from four London boroughs, and provides some tertiary services.  CRIS allows searching 
and retrieval of anonymised clinical records within robust technical and procedural safeguards 
(Fernandes et al, 2013).  Data can be extracted from free text (e.g. case notes and correspondence), 
using targeted keyword searches.  Structured data include socio-demographics (including ethnicity), 
year and month of birth, and referrals data including admissions to SLAM and movements within 
SLaM services such as wards and community teams.  Several natural language processing (NLP) 
applications on a General Architecture for Text Engineering (GATE) platform (Cunningham et al, 
2013) have been developed which derive structured data from free text and are validated against 
manual annotations.  These include diagnosis and medication (Perera et al, 2016).  CRIS was 
approved for research by Oxfordshire Research Ethics Committee C (08/H0606/71+5), and is linked 
to Hospital Episode Statistics: national data for inpatient, outpatient and accident and emergency 
attendances in England including maternity data.   
Study population 
A historic cohort was assembled of women pregnant from 2007-2011 whose pregnancies continued 
beyond first trimester.  We used maternity Hospital Episode Statistics (HES) indicating delivery of a 
baby linked to CRIS data indicating women with SMI, using ICD-10 diagnoses F20, F22, F23, F25, F28, 
F29 (schizophrenia and related disorders, schizoaffective disorders and delusional disorders), F30, 
F31 (mania and bipolar disorders), F32.3, F33.3 (psychotic depression), F53.1 (puerperal psychosis).  
CRIS data is complete from 2006 and at the time of data extraction, HES data was available up to the 
end of 2011.HES data indicated the end date of pregnancy.  In order to collect time dependent 
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variables, trimesters of pregnancy were dated using a modified validated algorithm (Li et al, 2013; 
Taylor et al, 2015).  CRIS data captured socio-demographic and clinical details regarding women’s 
mental health.  In order to be able to capture clinical details regarding women’s mental health in the 
perinatal period, we included women under SLaM care (therefore on CRIS) at any point from 6 
months before to 6 weeks after the HES delivery episode with SMI diagnoses during the 
preconception period so.  We excluded women whose illness was not in remission at the start of 
pregnancy, determined by admission to acute mental health care (inpatient or home treatment) in 
the three months before the start date of pregnancy.     
 
Measures 
Severe relapse 
The first severe relapse of SMI (hereafter termed relapse) occurring during pregnancy was 
measured.  This has previously been defined as hospitalisation (Wesseloo et al, 2015).  We defined it 
as admission to mental health inpatient care, referral for home treatment (services for acute mental 
health crisis in the UK, involving frequent home visits (Johnson et al, 2008)) or an episode of self-
harm (see (Taylor et al, 2016)) so that all significant relapses were included.  Admissions/ referrals 
were extracted from structured CRIS data or HES inpatient admissions to mental health trusts 
outside SLaM.  Self-harm during pregnancy was extracted using free text search terms previously 
validated in CRIS (Polling et al, 2015; Taylor et al, 2016). 
 
Socio-demographic characteristics for index (first) pregnancy  
Recorded ethnicity was categorised into ‘Black African/Caribbean/other’, ‘White British/other’, and 
‘Mixed, Asian or other/ not stated’.  Neighbourhood-level deprivation score was extracted closest in 
date to the beginning of pregnancy.  These give a summary measure of socioeconomic status at 
the level of the lower super output area (LSOA): a geographic unit containing a minimum of 
1000 residents and 400 households with an average nationally of around 1500 residents (Noble 
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et al, 2007).  Manual searches of CRIS free text using piloted terms established number of children 
prior to pregnancy, relationship status in pregnancy, history of childhood abuse and DV 
before/during pregnancy and family history of mental illness.  Recorded smoking in pregnancy was 
extracted by manual free text searches using terms (Wu et al, 2013).      
Mental disorder characteristics and severity at the beginning of pregnancy  
Diagnosis recorded at the start of pregnancy, extracted from CRIS structured fields and free text 
using an NLP application validated for dementia (Perera et al, 2016), was categorised into non-
affective and affective.  Non-affective SMI comprised schizophrenia, related psychoses, delusional 
disorders and schizoaffective disorders.  Affective SMI comprised bipolar disorder, psychotic 
depression and history of postpartum psychosis.  Where diagnosis was unclear, correspondence was 
scrutinised by a researcher and clinician. 
Number of days in acute mental health care in the two years before pregnancy was extracted from 
CRIS (supplemented with HES for outside-SLaM care (Taylor et al, 2015)) and spells of acute care 
defined as periods of treatment in acute care (inpatient or home treatment) with at most 7 days 
between discharge and readmission.  Time since last major episode was calculated from the 
beginning of the most recent ‘spell’ of acute care in the 2 years prior to conception.  Detention 
under the Mental Health Act (involuntary admission) in the 2 years before pregnancy was extracted 
from structured fields and free text.   
Manual free text searches of CRIS ascertained recorded alcohol and drug use in pregnancy within the 
previous 2 years, supplemented by substance misuse diagnoses from CRIS structured fields and an 
NLP application. Baseline level of functioning was estimated from the highest total adjusted score 
recorded in the two years before pregnancy from the Health of the Nation Outcome Scale (HoNOS), 
a routinely collected 12-item measure in UK mental health services of health and social functioning 
of people with severe mental illness (Wing et al, 1998) stored in CRIS. 
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Medication exposure in the first trimester of pregnancy 
Medication exposures were extracted from free text in CRIS, primarily  using an NLP application 
(validated for a number of antipsychotic agents (Kadra et al, 2015)) to extract structured indicators 
describing medication during the first trimester, supplemented by manual text searches.  The clinical 
documents were recalled and manually coded for information on medications not already validated.  
Stops, starts and switches in regular antipsychotics, mood stabilisers and antidepressants were 
noted, including whether stops occurred abruptly (over 1-14 days) or gradually (>14 days).  Where 
speed of discontinuation was not specified, women were coded as stopping abruptly.  Recorded 
non-adherence to medication was categorised if there was written concern about this.  Two 
researchers rated medication, with consensus meetings to resolve uncertainties; a consecutive (26 
pregnancies) were rated for identification of antipsychotic, mood stabiliser and antidepressant with 
inter-rater agreements of 97%. For the main analysis, medication was categorised as ‘stopped or 
switched’ if a woman had a stop and/or switch in a regular medication, ‘continued’ if a woman 
continued a regular medication all the way through the first trimester and did not stop or switch a 
regular medication, and ‘no medication at start of pregnancy’ if a woman was not on any regular 
medication at the start of 1
st
 trimester.  Further detail including exposures to individual medications 
and medication types in 3 months before pregnancy and 1
st
 trimester is provided elsewhere (Taylor 
et al, 2015). 
Data analysis 
 
Data were analysed using STATA 12.  After initial descriptive analyses of women, subsequent 
analyses were carried out by pregnancy.  Incidence and timing (by trimester) of relapses during 
pregnancy were reported for the whole sample and stratified by baseline diagnosis.  To account for 
non-independent data in women who contributed more than one pregnancy during the study 
period, all subsequent statistical analyses were carried out using random effects logistic regression.  
Only one indicator of acute mental health care before pregnancy – number of admissions – was used 
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in multivariable analyses following chi
2
 tests for association between them to assess colinearity.  We 
used purposeful selection of variables (Bursac et al, 2008), and predictors with p≤0.2 from 
unadjusted analyses were added simultaneously to the model and unadjusted and fully adjusted 
effect sizes compared.  Predictors with a fully adjusted p-value of >0.5 were removed from the final 
model.  Given our main hypothesis around medication; we ran post-hoc analyses using chi
2
 tests to 
assess association of covariates with the medication variable using the 3 category medication 
variable as an outcome and random effect logistic regression to look at the association of medication 
with relapse adjusted for each covariate separately to investigate confounding of the association 
with medication and relapse.  Following a post-hoc test for colinearity between smoking and harmful 
substance use we ran the multivariable model excluding harmful substance use. Since women on no 
medication may be non-adherent or psychiatrically stable, we ran a test for the interaction of 
psychiatric stability (admission in the 2 years before pregnancy) and medication on relapse.  Most 
research has investigated bipolar disorder so we also tested the interaction of medication with 
diagnosis on relapse and ran the analysis stratified by diagnostic group (affective/ affective), 
reclassifying medication into two categories – continued versus stopped/switched/no medication.  
All interaction tests used the likelihood ratio. 
 
A number of sensitivity analyses were carried out.  To address issues of reverse causality for 
medication change and relapse both occurring in the first trimester, pregnancies with first trimester 
relapses were excluded, followed by an evaluation, censoring pregnancies which ended in the 2
nd
 
trimester.  For comparability with other investigations of admissions in pregnancy, a sensitivity 
analysis excluded self-harm from the definition of relapse.  To compare with previous studies on 
stopping medication and stopping abruptly in pregnancy (Viguera et al, 2007), women who switched 
a medication only were excluded from the ‘stopped or switched’ group (statistical power was 
insufficient to analyse switching separately) and we further excluded those stopping medication 
gradually.  A further analysis excluded women with possible non-adherence in case of 
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misclassification and we also reclassified women who continued a medication but were coded non-
adherent into the stopped/switched group. Finally we looked at the unadjusted and adjusted 
associations with stopping versus switching/ continuing an antidepressant, mood stabiliser and 
antipsychotic separately. 
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Results 
 
Sample characteristics 
 
There were 454 pregnancies in 389 women with history of SMI (Figure 1).  Fifty-two (13.4%) women 
had more than one pregnancy in the study period (number of pregnancies per woman ranged from 
1-5).  Table 1 displays demographic and clinical characteristics of women.  Of 203 (52.2%) women 
with diagnoses of non-affective SMI, 112 (28.8%) had diagnoses of schizophrenia or delusional 
disorder, 27 (6.9%) with schizoaffective disorder and 64 (16.5%) had other non-affective diagnoses 
including acute and transient psychosis; 186 (47.8%) women had affective diagnoses including 
bipolar disorder (138 women, 35.5%), depressive psychosis (41 women, 10.5%) and history of 
postpartum psychosis (7 women, 1.8%).  Comorbid diagnoses between 9 months and 2 years before 
delivery episode included 18 (4.6%) women with substance use diagnoses, 9 (2.3%) with personality 
disorder diagnoses, 11 (2.8%) with anxiety disorders, 6 (1.5%) with learning difficulties and <5 with 
other diagnoses including eating disorders, conduct disorders and epilepsy.   
 
In 454 pregnancies, there were 83 (18.3%) relapses, including 74 (16.3%) admissions to acute care 
(inpatient or home treatment), with 26 (5.7%) relapses occurring in the first trimester and 32 (7.5%) 
in the second.  Thirteen pregnancies ended in the second trimester, and of 383 remaining 
pregnancies a further 25 (6.5%) relapsed in third trimester.  All admissions to the mother and baby 
unit were for acute mental health reasons.  Supplementary Table 1 provides further detail on 
relapses by trimester and diagnosis.    
 
First trimester medication (antidepressant, mood stabiliser or antipsychotic) exposures were as 
follows: 147 (15.7%) no regular medication, 240 (52.9%) receiving an antipsychotic, 67 (14.8%) a 
mood stabiliser and 106 (23.4%) an antidepressant; 188 (41.4%) exposed to one agent only, 88 
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(19.3%) exposed to two and 31 (6.8%) to more than two.  Table 1 shows medication categories in the 
1
st
 trimester as used for analysis.  Medication categories were associated strongly from one 
trimester to the next; from 3 months before pregnancy to 1
st
 trimester, chi
2
=312.64, p<0.001, from 
1
st
 to 2
nd
 trimester, chi
2
=296.41, p<0.001 and from 1
st
 to 3
rd
 trimester, chi
2
=182.34, p<0.001.   
 
Deprivation scores were missing for 18 (4.0%) pregnancies. HoNOS scores were missing for 212 
(46.7%).   
 
Socio-demographic and clinical characteristics associated with relapse in pregnancy (Table 2) and 
associated with medication exposures (supplementary table 2).   
 
Relapse in pregnancy was significantly associated with non-white ethnicity, DV, smoking, non-
affective psychosis, substance misuse, admissions in the two years before pregnancy, less than 2 
years since previous acute admission, and self-harm in the 2 years before pregnancy.  Very similar 
results were found when relapses in the 1st trimester were excluded.  Women who continued to 
take medication had fewer relapses than women who were medication free or stopped/switched 
medication but this was not statistically significant.  Age, history of admissions variables, self-harm 
and smoking in pregnancy were distributed differently across medication groups.  Average age was 
highest in the continued medication group.  Women with pregnancies unexposed to medication 
tended to have less admissions or time in acute care in the two years before pregnancy. Rates of 
self-harm were highest in those who stopped or switched a medication and lowest in those who 
continued.  Recorded smoking was highest in those who stopped or switched medication and lowest 
in those unexposed to medication at the beginning of pregnancy.   
 
Multivariable analysis 
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In the fully adjusted model (Table 3), (adjusted for medication group, admissions and self-harm in 2 
years before pregnancy, diagnosis at baseline, harmful substance use, smoking in pregnancy and 
ethnicity) relapse was independently associated with non-affective psychosis, illness severity 
(admissions and self-harm in two years before pregnancy), substance misuse, smoking in pregnancy 
and non-white ethnicity.  Given substance misuse and smoking were strongly associated (p<0.001), 
we also ran the model excluding substance misuse which made no difference to our findings.  
Women not on medication were more likely to relapse than women who continued medication; 
stopping or switching medication was not associated with increased risk of relapse (Table 3 & 4). 
However, when first trimester relapses were excluded, the association between being on no 
medication and relapse was attenuated (adjusted OR=1.43; 95%CI 0.69-2.98). Post-hoc analysis 
showed the association with relapse was most confounded by admissions in 2 years before 
pregnancy and smoking (supplementary table 3).  Stratified by affective/ non-affective diagnosis 
(Supplementary Table 4), findings were similar, though due to smaller numbers most associations 
did not reach statistical significance.  No significant interactions were found on risk of relapse 
between medication and affective/ non-affective diagnosis (chi2=0.01, p=0.922) and medication and 
admissions in the 2 years before pregnancy (chi2=0.52, p=0.471), or between DV and medication 
status (chi2=1.34, p=0.248).  
 
Sensitivity analyses 
 
Defining relapse by acute admissions only (n= 74 relapses) made little difference to results. Excluding 
pregnancies where medication was stopped gradually (n=13) made no meaningful difference (Table 
4).  Excluding those with recorded non-adherence to address potential misclassification of 
medication (17 pregnancies) strengthened the unadjusted difference between continuing vs. 
stopping/switching medication, but multivariable output remained similar (Supplementary Table 5).  
Exclusion of 14 pregnancies which ended in 2
nd
 trimester made no difference (supplementary table 
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6).  There was no association between these early ending pregnancies and relapse (Fisher’s exact, 
p=0.482).  Women who stopped an antipsychotic had higher odds of relapse than women who 
continued/ switched, but this was not the case for mood stabilisers or antidepressants.  
However these findings were not significant (supplementary table 7). 
 
Discussion 
In 389 women with SMI, there were 83 (18.3%) relapses during 454 pregnancies – 58 (24.4%) in 
pregnancies of women with non-affective diagnoses and 25 (11.6%) in women with affective 
disorders.  Based on multivariable analyses, the nature and severity of the mental disorder (non-
affective psychosis at baseline, recent admissions, harmful substance use, and recent self-harm) was 
associated with relapse in pregnancy.  Smoking and non-white ethnicity also independently 
predicted relapse.  Continuing medication compared with not taking medication at the beginning of 
pregnancy was protective, but we were unable to draw conclusions about switching or stopping 
medication in the first trimester.   
These findings provide some reassurance that although relapse can occur in pregnancy, most 
women in this cohort did not have episodes needing acute care or manifesting as self-harm.  Our 
findings suggest that risk of relapse in women with bipolar disorder may be lower than in studies of 
women attending specialist clinics (Viguera et al, 2011; Viguera et al, 2007), and comparable with 
the few studies carried out on more representative samples (Judd et al, 2014). There are few data in 
women with non-affective psychoses.  The only other large study to date, which used administrative 
data, found that 24% of pregnant women with schizophrenia were admitted or visited a mental 
health emergency service, which is comparable to our findings (Vigod et al, 2014). 
There has been little previous research into risk factors for relapse of severe mental disorder in 
pregnancy, although associations with severity of the pre-existing psychiatric illness have been 
reported (Munk-Olsen et al, 2009; Vigod & Ross, 2010; Viguera et al, 2007).  Using comprehensive 
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clinical data we found that smoking, recent self-harm and substance misuse also showed 
associations with relapse, potentially suggesting higher-risk lifestyles.  Such women may find it more 
difficult to prioritise stopping smoking or substance use in pregnancy; alternatively, smoking and 
substance misuse may be associated with worsening mental health. Both are important risk factors 
for adverse fetal outcomes (Stein et al, 2014), which need to be addressed by services.  Being of 
black ethnicity was also associated with increased risk of relapse in pregnancy, consistent with 
research showing higher rates of relapse and worse outcomes in people of black compared with 
white ethnicity (Mann et al, 2014).  Non-affective diagnosis has also been associated with worse 
outcomes in patients with psychosis (Morgan et al, 2014) as well as non-adherence to medication 
(Porcelli et al, 2016).  Relapse or psychiatric admission in pregnancy may be an important predictor 
of relapse postpartum and further work with this cohort has looked at relapse in the first three 
months postpartum including admission in pregnancy as a predictor. 
We did not find an association between medication discontinuation or switching and relapse, in 
contrast to others (Viguera et al, 2007) who found 86% risk in women with bipolar disorder stopping 
mood stabilising medication compared with 37% in women who continued, independent of disorder 
severity measures. Different definitions of relapse may explain some of this heterogeneity.  In 
Viguera’s study, it could not be determined whether medication change in the first trimester 
occurred before or after a relapse in early pregnancy; however, excluding women who relapsed in 
the first trimester attenuated our association, and indeed Viguera’s data showed particularly high 
risk of relapse in early pregnancy.  In observational research, independent effects of psychiatric 
illness and medication can be challenging to disentangle.  Different classification of medication 
exposures may also explain some discrepancy in findings. Viguera investigated stopping mood 
stabilisers from 6 months before to 12 weeks after conception and excluded women who stopped 
medication over 6 months before.  In our data women who stopped medication before pregnancy 
would be in the ‘no medication’ group and tended to relapse early.   
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To our knowledge, there are no comparative data in pregnant women with schizophrenia; however, 
outside the perinatal period, switching medication appears well tolerated (Roussidis et al, 2013).  
These clinical records enabled us to investigate potential impact of other moderators, notably DV. 
This needs replication in larger samples but its potential adverse impact on mental health is reported 
elsewhere (Khalifeh et al, 2015) as is the importance of addressing DV perinatally (NICE, 2014). 
A major strength of this study was the novel methodology using electronic secondary mental health 
data.  This allowed investigation of a larger cohort of women than previous clinical studies, with 
more detail on illness severity and other psychosocial characteristics than population registries.  
SLaM provides near-monopoly secondary mental health services to its catchment, so these data are 
likely to include most pregnant women with SMI in this locality.  The linkage with HES enabled us to 
collect psychiatric admissions data covering England, minimising loss to follow-up and giving a full 
picture of illness history for this dynamic cohort.  We were also able to collect data on recorded DV, 
substance use and self-harm.  Detailed clinical data on medication enabled us to capture changes 
resulting from mutual decisions made under clinical guidance (Swanson et al, 2015) or self-initiated 
cessation decisions, as well as recorded adherence, so we were able to address some 
misclassifications not achievable with registry data.  CRIS data are not collected for research and rely 
on accuracy and comprehensiveness of clinical note keeping.  Although we used multiple validated 
search terms, some information may be absent or underreported, such as that on smoking.  We 
were not able to ascertain previous history of perinatal episodes which have been shown predictive 
of postpartum relapse.  However, this methodology enabled us to observe this high-risk group of 
pregnant women in a real-world setting.  We were able to include self-harm and women potentially 
more severely at risk than may take part in clinical studies.   
Considering sample selection, our data source does not include women managed only in primary 
care.  However, the threshold for referral to secondary care may be lower in pregnancy, and national 
guidelines (NICE, 2014) recommend referral of pregnant women with SMI history to secondary 
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mental health care.  There may also be selection into pregnancy in women with SMI, since reported 
fertility is lower than that in the general population (Howard et al, 2002; Vigod et al, 2012).  
Schizophrenia may  affect relationship stability (Howard, 2005) and there are also reported higher 
rates of termination (Laursen & Munk-Olsen, 2010) and unplanned pregnancies in women with SMI 
(Miller & Finnerty, 1996).  These factors affect comparability with times outside pregnancy.  The 
linkage to HES data allowed a robust method of identifying pregnancies, covering deliveries across 
England.  Home births are thought to be under recorded in HES (2.4% of deliveries in England in 
2011 were at home) (ONS, 2013) though pregnancies in women with SMI are considered high-risk 
obstetrically so home births may be less likely.  The retrospective design may have identified a 
particularly severe group of women since by default women admitted in pregnancy would have been 
included in the cohort.  Women also receive many diagnoses in the health records; therefore, 
potential misclassification may have affected inclusion.   
Considering the outcome, admission to acute care may not be a sensitive indicator of relapse, as less 
severe relapses may be managed by the secondary services already providing care, or by medication 
changes.  Whilst using this endpoint may have missed some cases of relapse, it may also have 
included women admitted for social reasons, thus reflecting socio-economic disadvantage rather 
than relapse per se.  However, all admissions to the MBU during pregnancy were for acute illness so 
this is unlikely to have skewed the results significantly.  We did not carry out survival analyses as 
dates of admission were considered to be insufficiently accurate estimates of end-point timing.   
Considering exposures, the stopped/switched medication group may be heterogeneous in terms of 
reasons for stopping/switching.  However most women who stopped medication in the first 
trimester did so because of pregnancy (Taylor et al, 2015) and sensitivity analyses excluding 
switchers and gradual stoppers made little difference to findings.  We did not have the power to 
analyse gradual stoppers separately and there may have been some misclassification of speed of 
stopping medication as it was difficult to determine from the clinical notes and we assumed abrupt 
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stopping unless stated otherwise.  Previous research has shown that women with bipolar disorder 
may have higher risk of relapse if they discontinue or do not take medication.  Women with non-
affective psychosis may not be the same.  However we did not have a large enough sample to 
ascertain predictors or moderators of relapse separately in the non-affective and affective groups. 
The fairly small proportion of relapses detected limited statistical power to detect some 
associations, and larger cohorts would be needed to address some remaining questions.  Prospective 
clinical research could address some of the issues of unrecorded clinical information although 
assembling a large cohort would be costly and time-consuming with higher risk of attrition bias.   
Conclusions 
Women with indicators of more severe SMI are more likely to relapse in pregnancy, these indicators 
including having more admissions in the two years prior to pregnancy, non-affective illness, history 
of self-harm, smoking and substance use.  We found weaker evidence of association with medication 
change but women on no medication at the start of pregnancy were more likely to relapse in early 
pregnancy. While the risks and benefits of taking medication in pregnancy must be weighed up for 
each individual (NICE, 2014) this study has identified those at particularly high risk of relapse in 
pregnancy – evidence that could be shared with women who are making decisions about medication 
in pregnancy.  Women with SMI have multiple risk factors for adverse pregnancy outcomes including 
risk of relapse, smoking, substance use, medication and should be under care of specialist services 
during pregnancy.  Attention should also be paid to potentially modifiable risk factors including 
smoking and substance use. 
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Table 1: Socio-demographic and clinical characteristics of 389 pregnant women with severe 
mental illness 
 N=389 
Diagnosis at beginning of pregnancy, N(%)     
  Affective  186 (47.8) 
  Non affective  203 (52.2) 
Ethnicity, N(%)     
  White British & other White  132 (33.9) 
  Black African & other Black  188 (48.3) 
  Asian/ Mixed/ Other  69 (17.7) 
Deprivation score, median(range)
1
  34.9 (4.8,61.5) 
Maternal age at 1
st
 index delivery, mean(SD), 31.8 (6.1) 
Partner during 1
st
 index pregnancy  269 (69.2) 
Number of children at 1
st
 index pregnancy, N(%)   
  0 182 (46.8) 
  1 103 (26.5) 
  ≥2 104 (26.7) 
Recorded history of child abuse, N(%) 78 (20.1) 
Recorded domestic abuse before/during pregnancy, N(%) 133 (34.2) 
Smoking in pregnancy, N(%)   69 (17.7) 
Harmful substance use, N(%) 96 (24.7) 
Self-harm in 2 years before pregnancy, N(%) 54 (13.9) 
Number of days of acute care in 2 years before pregnancy, N(%)  
  0 235 (60.4) 
  1-30 53 (13.6) 
  31-60 43 (11.1) 
  61+ (-537) 58 (14.9) 
Number of acute admissions in 2 years before pregnancy, N(%)  
  0 235 (60.4) 
  1 103 (26.5) 
  2 30 (7.7) 
  >2 21 (5.4) 
Time since last acute admission, N(%)  
  None in 2 years before pregnancy 235 (60.4) 
  1 year 79 (20.3) 
  2 years 75 (19.3) 
MHA
3
 in 2 years before pregnancy, N(%) 67 (17.2) 
Highest HoNOS total adjusted score in 2 years before 
pregnancy, median (range)
2
 
12 (0-36) 
Family history of any mental illness, N(%) 168 (43.2) 
Medication changes 1
st
 trimester, N(%)  
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  Continued 145 (37.3) 
  Stopped and/or  switched 105 (27.0) 
  No medication at start 139 (35.7) 
1: n=374, 2: n=196, 3: detained under section 2 or 3 of the mental health act 
  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2 – Socio-demographic and clinical characteristic, and associations with relapse in pregnancy episodes (n=454)   
 N N(%) relapse in pregnancy (n=83) Odds ratio (95% CI) p-value 
Baseline Diagnosis        
  Affective  216 25 (11.6) Ref  
  Non affective  238 58 (24.4) 2.58 (1.45,4.58) 0.001* 
Ethnicity        
  White British & other White 221 49 (22.2) Ref  
  Black African & other Black 154 17 (11.0) 2.50 (1.24,5.04) 0.010* 
  Asian/ Mixed/ Other  79 17 (21.5) 2.31 (1.01,5.25) 0.047* 
Partner during pregnancy
2
  321 58 (18.1) 0.94 (0.53,1.65) 0.826 
Children at index pregnancy      
  0 188 35 (18.6) Ref  
  1 127 25 (19.7) 1.06 (0.58,1.98) 0.836 
  ≥2 139 23 (16.6) 0.83 (0.44,1.57) 0.563 
Victim of child abuse
2
 96 22 (22.9) 1.44 (0.80,2.60) 0.221 
Victim of domestic abuse before 
or during pregnancy
2
 
167 39 (23.4) 1.74 (1.02,2.98) 0.044* 
Smoking in pregnancy
2
  79 31 (39.2) 4.47 (2.23,8.99) <0.001* 
Harmful substance use
2
 109 36 (33.0) 3.37 (1.82,6.21) <0.001* 
Self-harm in 2 years before 
pregnancy
2
 
61 23 (37.7) 3.60 (1.83,7.10)* <0.001* 
Number of days of acute care in 
2 years before pregnancy,  
    
  0 270 38 (14.1) Ref  
  1-30 65 18 (27.7) 2.34 (1.22,4.48)* 0.010* 
  31-60 46 8 (17.4) 1.28 (0.56,2.97)
 a
 0.558* 
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  61+ 73 19 (26.0) 2.15 (1.15,4.02) 0.017 
  Linear association 454 83 (18.3) 1.01 (1.00,1.02)* 0.091 
Number of acute admissions in 2 
years before pregnancy 
    
  0 270 38 (14.1) Ref  
  1 121 25 (20.7) 1.59 (0.91,2.79)
 
 0.107 
  2 39 11 (28.2) 2.40 (1.10,5.26)* 0.029* 
  >2 24 9 (37.5) 3.67 (1.47,9.25)* 0.005* 
  Linear association 454 83 (18.3) 1.55 (1.20,2.01)* <0.001* 
MHA
1
 2 years before pregnancy
2
 77 16 (20.8) 1.18 (0.61,2.28)
 
 0.663 
Time since last admission (years)     
  Not in 2 years before pregnancy 270 38 (14.1) Ref  
  <1 year 99 30 (30.3) 2.66 (1.53,4.63) 0.001* 
  1-2 years 85 15 (17.7) 1.31 (0.68,2.52)
 
 0.425 
Family history of mental illness
2
 199 40 (20.1) 1.23 (0.74,2.04) 0.432 
Medication change 1
st
 trimester     
  Continued/ no stop or switch 173 25 (14.5) Ref  
  Stopped and/ or Switched 118 25 (21.2) 1.66 (0.85,3.26) 0.140 
  No medication  163 33 (20.3) 1.60 (0.84,3.06) 0.153 
Deprivation score (per unit increase), (n=436) 1.02 (0.99,1.04) 0.147 
Maternal age at delivery (per year increase), (n=454) 0.96 (0.92,1.01) 0.091 
Highest HoNOS total adjusted score in 2 years before pregnancy (per unit increase), n=242 1.01 (0.97,1.06) 0.599 
1
: detained under section 2 or 3 of the Mental Health Act; *p<0.05 
2
: for partner during pregnancy, victim of child/ domestic abuse, smoking/ harmful substance use, MHA admission and family history of mental illness 
variables, the reference group was ‘no’ and ‘absent information’ combined 
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Table 3:  Multivariable analysis of predictors of relapse in pregnancy 
 Relapse in pregnancy,  
odds ratios (95% CI); N=454, n=83 relapses 
Relapse in 2
nd
 or 3
rd
 trimester,  
odds ratios (95% CI); N=428, n=57 relapses 
 Unadjusted Fully adjusted Unadjusted Fully adjusted 
Medication      
  Continuation Ref Ref Ref Ref 
  Stopped/ switched 1.66 (0.85,3.26), 0.140 1.30 (0.66,2.58), 0.446 1.41 (0.67,2.95), 0.363 1.16 (0.55,2.45), 0.703 
  No medication  1.60 (0.84,3.06), 0.153 1.99 (1.05,3.75), 0.034 1.01 (0.49,2.09), 0.977 1.43 (0.69,2.98), 0.335 
Number of admissions in last 
2 years 
1.55 (1.20,2.01), 0.001 1.37 (1.03,1.84), 0.033 1.68 (1.26,2.23),<0.001 1.49 (1.08,2.05),0.015 
Non-affective diagnosis at 
baseline 
2.58 (1.45,4.58), 0.001 2.03 (1.16,3.54), 0.013 2.55 (1.35,4.81),0.004 2.06 (1.08,3.94),0.028 
Self-harm in last 2 years  3.60 (1.83,7.10),<0.001 2.24 (1.15,4.34), 0.017 3.25 (1.38,7.66),0.007 1.87 (0.87,4.03), 0.109 
Harmful Substance use 3.37 (1.82,6.21),<0.001 2.15 (1.13,4.08), 0.019 2.83 (1.37,5.83),0.005 1.59 (0.74,3.41), 0.231 
Smoking in pregnancy 4.47 (2.23,8.99),<0.001 2.52 (1.26,5.02), 0.009 4.11 (1.83,9.22), 0.001 2.72 (1.21,6.09), 0.015 
Ethnicity     
  White Ref Ref Ref Ref 
  Black 2.50 (1.24,5.04), 0.010 2.37 (1.23,4.57), 0.010 2.92 (1.31,6.50), 0.009 2.79 (1.26,6.18), 0.014 
  Mixed/ Other 2.31 (1.01,5.25), 0.047 2.94 (1.32,6.56), 0.008 2.65 (1.04,6.77), 0.042 3.29 (1.27,8.53), 0.014 
Based on predictors with p<0.2 from bivariate analysis.  Maternal age at delivery, deprivation score and domestic abuse were removed from the final model 
as they had a fully adjusted p>0.5 
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Table 4:  Sensitivity analyses to investigate stopping medication in 1
st
 trimester 
 Excluding pregnancies with only a switch in 
medication,  
odds ratios (95% CI); N=436, n=79 relapses 
Stopping medication abruptly (excluding only 
switchers and gradual stoppers),  
odds ratios (95% CI); N=422, n=75 relapses 
 Unadjusted Fully adjusted Unadjusted Fully adjusted  
Medication      
  Continued Ref Ref Ref Ref 
  Stopped  1.65 (0.81,3.37), 0.170 1.30 (0.63,2.68), 0.475 1.48 (0.70,3.11), 0.302 1.16 (0.53,2.53), 0.704 
    No medication at start 1.61 (0.84,3.10), 0.152 1.99 (1.03,3.84), 0.040 1.62 (0.85,3.11), 0.146 2.09 (1.06,4.13), 0.033 
Number of admissions in 
2 years before 
1.52 (1.16,2.00), 0.003 1.39 (1.03,1.88), 0.034 1.52 (1.16,2.00), 0.003 1.40 (1.02,1.93), 0.038 
Baseline diagnosis 2.56 (1.41,4.63), 0.002 1.99 (1.12,3.53), 0.019 2.56 (1.41,4.63), 0.002 2.01 (1.10,3.68), 0.023 
Self-harm in 2 years 
before pregnancy 
3.01 (1.49,6.08), 0.002 2.12 (1.05,4.28), 0.039 3.01 (1.49,6.08), 0.002 2.08 (1.00,4.35), 0.051 
Harmful substance use 2.95 (1.57,5.54), 0.001 2.01 (1.02,3.95), 0.042 2.95 (1.57,5.54), 0.001 1.97 (0.96,4.03), 0.063 
Smoking 4.28 (2.06,8.89),<0.001 2.44 (1.16,5.10), 0.018 4.28 (2.06,8.89),<0.001 2.75 (1.24,6.09), 0.012 
Ethnicity     
  White Ref Ref Ref Ref 
  Black 3.16 (1.43,6.98), 0.022 2.54 (1.20,5.38), 0.015 4.18 (1.72,10.19),0.002 3.40 (1.45,8.00), 0.005 
  Mixed/ Other 2.84 (1.16,6.96), 0.005 3.12 (1.33,7.35), 0.009 3.52 (1.33,9.34), 0.012 4.21 (1.61,11.00),0.003 
Based on predictors with p<0.2 from bivariate analysis.  Maternal age at delivery, deprivation score and domestic abuse were removed from the final model 
as they had a fully adjusted p>0.5 
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